Overview

Real-World Evidence of Anticoagulation Treatment In Non-Valvular Atrial Fibrillation In Italy

Status:
Active, not recruiting

Trial end date:
0000-00-00

Target enrollment:
40900

Participant gender:
Both

Summary

To quantify rates of bleeding events and investigate the characteristics of prescribed patients, rates of bleeding events, persistence and healthcare resource utilization of Oral Anticoagulants (OACs) prescribed in routine clinical practice.

Phase:

N/A

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Bristol-Myers Squibb

Collaborator:

Pfizer

Treatments:

Apixaban
Dabigatran
Rivaroxaban

Last Updated:

2016-09-29

Criteria

Inclusion Criteria:

- are at least 18 years of age at index date

- Initiated new OAC therapy ( no previous prescriptions of the same index OAC in the
last 12 months prior to the index date ) during the study period

- Had at least 1 claim with diagnosis of AF anytime in their records

Exclusion Criteria:

- Have a record that is indicative of Valvular Atrial Fibrillation during this period

- Have a history of the OACs prescribed during the study period as assessed during the
period of data availability(i.e. history of index OAC, as patients need to be newly
prescribed either apixaban, rivaroxaban, dabigatran or VKA)

- Have more than one OAC exposure which starts on the same date